Infoblox Announces Pending Resignation of CEO; Retrophin Inc. Enters into U.S. License Agreement with Mission Pharmacal Co.

Follow this company

Companies Mentioned

06/02/2014 [ACCESSWIRE]

Infoblox Inc. (NYSE: BLOX) shares closed down nearly 37% this past Friday on about 30 million shares traded. The stock was one of the biggest decliners on the NYSE and hit a new yearly low of $12.01 during intra-day trading. The drop came after the company reported mixed third-quarter results and weak forward guidance. Infoblox also announced the pending resignation of its CEO.

Infoblox Inc. develops, markets, and sells automated network control solutions worldwide. Its appliance-based solution combines real-time IP address management with the automation of network control, and network change and configuration management processes in physical and virtual appliances.

Get more information on Infoblox Inc. and free access to the in depth equity report at: wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at to get full access to our free stock reports.

Retrophin, Inc. (NASDAQ: RTRX) shares closed up 13.51% on nearly 3.5 million shares traded. The stock was one of the biggest winners on the NASDAQ. The company announced that it had arranged for $80 million worth of term loans and has entered into a U.S. license agreement with privately held Mission Pharmacal Co. for the marketing rights to Thiola, a treatment for cystinuria, a rare genetic cysteine transport disorder.

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. It sells Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; and Vecamyl for the treatment of hypertension.

Get more information on Retrophin, Inc. and free access to the in depth equity report at”


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures. 


Leave a comment...

Your Name